Breaking News

Home Depot Says 56 Million Payment Cards at Risk From Hack
Tweet TWEET

Aegerion Pharmaceuticals Prices Public Offering of Common Stock

Aegerion Pharmaceuticals Prices Public Offering of Common Stock

CAMBRIDGE, Mass., Jan. 11, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc. (Nasdaq:AEGR) ("Aegerion"), a biopharmaceutical company dedicated to the
development and commercialization of innovative, life-altering therapies for
patients with debilitating and often fatal rare diseases, today announced the
pricing of an underwritten public offering of 2,704,739 shares of common stock
at a price to the public of $26.64 per share. The net proceeds to Aegerion
from this offering are expected to be approximately $67.9 million, after
deducting underwriting discounts and commissions. The offering is expected to
close on January 16, 2013, subject to customary closing conditions.

Jefferies & Company, Inc. and J.P. Morgan Securities LLC are acting as joint
book-running managers in the offering. Leerink Swann LLC, Canaccord Genuity
Inc., and Cowen and Company, LLC are acting as co-managers for the offering.
Aegerion has granted the underwriters a 30-day option to purchase up to an
aggregate of 405,710 additional shares of common stock. Aegerion anticipates
using the net proceeds from the offering to fund activities directed at
commercial launch of JUXTAPID™ (lomitapide) Capsules in the United States;
pursuing approval of its Marketing Authorization Application submission with
the European Medicines Agency for lomitapide, and, if it is approved,
commercial activities in the European Union; expansion of operations in
certain countries to pursue regulatory approval of lomitapide and to conduct
sales on a named-patient-sales basis, where permitted; advancement of the
clinical development of lomitapide; and business development activities; with
any remainder to fund working capital, capital expenditures and for general
corporate purposes.

The securities described above are being offered by Aegerion pursuant to shelf
registration statements previously filed with and declared effective by the
Securities and Exchange Commission (the "SEC").A preliminary prospectus
supplement related to the offering has been filed with the SEC.A final
prospectus supplement related to the offering will be filed with the SEC.The
preliminary prospectus supplement is available, and the final prospectus
supplement will be available, on the SEC's website at http://www.sec.gov. In
addition, copies of the preliminary prospectus supplement and theaccompanying
prospectus, and the final prospectus supplement and accompanying prospectus,
when available, may be obtained from Jefferies & Company, Inc., Equity
Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY,
10022, or by telephone at 877-547-6340, or by email at
Prospectus_Department@Jefferies.com; or J.P. Morgan Securities LLC, c/o
Broadridge Financial, 1155 Long Island Avenue, Edgewood, New York 11717 or by
telephone at 1-866-803-9204.

This release shall not constitute an offer to sell or the solicitation of an
offer to buy these securities, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer, solicitation or sale
would be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the
development and commercialization of innovative, life-altering therapies for
patients with debilitating, often fatal, rare diseases.

The Aegerion Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=16441

Forward-Looking Statements

This press release contains forward-looking statements, including statements
related to the closing of Aegerion's public offering of common stock and the
anticipated use of proceeds from the offering, including references to the
commercial launch of JUXTAPID in the United States, the possible approval of
lomitapide in the European Union and other countries and the commencement of
commercial activities in the European Union, if lomitapide is approved, and
advancing the clinical development of lomitapide. These forward-looking
statements are neither promises nor guarantees of future performance, and are
subject to a variety of risks and uncertainties, many of which are beyond
Aegerion's control, which could cause actual results to differ materially from
those contemplated in these forward-looking statements. In particular, the
risks and uncertainties with respect to the offering and anticipated use of
proceeds include, among other factors: risks and uncertainties associated with
market conditions and satisfaction of customary closing conditions related to
the proposed offering, risks associated with Aegerion's ability to satisfy
Aegerion's obligations to close the proposed offering and the risk that
Aegerion will not use the proceeds from the offering in the manner
contemplated. The risks and uncertainties with respect to the commercial
launch of JUXTAPID in the United States, the possible approval of lomitapide
in the European Union and other countries and the commencement of commercial
activities in the European Union, if lomitapide is approved, and advancing the
clinical development of lomitapide include: the risk that any delay or
technical hurdle in completion of our validation work may delay availability
of JUXTAPID for launch; the risk that regulatory authorities in the European
Union or other countries outside the United States may not be satisfied with
the efficacy or safety profile of lomitapide or our proposed risk management
plan; the risk that we do not receive approval of lomitapide in the European
Union or other countries outside the United States on a timely basis, or at
all; the risk that technical hurdles may delay initiation of future clinical
trials; the risks of unexpected results in our additional nonclinical or
clinical development work with lomitapide; and the other risks inherent in
drug development and the regulatory approval process. For additional
disclosure regarding these and other risks, see the disclosure contained in
Aegerion's public filings with the SEC (available on the SEC's website at
http://www.sec.gov), including the "Risk Factors" section filed as an exhibit
to Aegerion's Current Report on Form 8-K filed on January 10, 2013 and in the
preliminary prospectus supplement and related prospectus relating to the
proposed offering filed with the SEC on January 10, 2013. Aegerion undertakes
no obligation to update or revise the information contained in this press
release, whether as a result of new information, future events or
circumstances or otherwise.

CONTACT: Aegerion Pharmaceuticals, Inc.
         Investors
         Michael Lawless, VP, IR
         + 1 (857) 242-5028

Aegerion Pharmaceuticals, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.